2015—2020年我国7城市105家医院抗乙型肝炎病毒药物使用分析  

Analysis on the application of anti-HBV agents in 105 hospitals in 7 cities in my country from 2015 to 2020

作　　者：陈志强 孟文爽 刘炜 韩丽荣 史卫忠[2] 王乔宇 赵志刚[2] CHEN Zhi-qiang;MENG Wen-shuang;LIU Wei;HAN Li-rong;SHI Wei-zhong;WANG Qiao-yu;ZHAO Zhi-gang(Department of Pharmacy,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China;Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100160,China;Department of Obstetrics and Gynecology,Beijing Ditan Capital Medical University,Beijing 100015,China)

机构地区：[1]首都医科大学附属北京佑安医院药学部,北京100069 [2]首都医科大学附属北京天坛医院药学部,北京100160 [3]首都医科大学附属北京地坛医院妇产科,北京100015

出　　处：《临床药物治疗杂志》2022年第10期11-16,共6页Clinical Medication Journal

摘　　要：目的 分析2015—2020年我国7城市105家医院抗乙型肝炎病毒药物应用情况。方法 随机抽取参与中国药学会医院处方分析课题组研究的乙型肝炎患者的处方信息,并计算抗乙型肝炎病毒药物的用药频度(DDDs)、限定日费用、销售金额排序(B)与DDDs排序(A)的比值和销售金额,对临床应用情况进行分析。结果 共抽取乙型肝炎患者处方/医嘱数据2 999 191条,涉及7个城市105家医院。乙型肝炎患者的就诊人次及抗病毒药物总金额呈先上升后下降的趋势,男性患者明显多于女性患者。2015—2017年,使用频度前2位的抗病毒药物是恩替卡韦和阿德福韦酯,2018—2020年,则是恩替卡韦和替诺福韦二吡呋酯。2015—2020年,富马酸替诺福韦二吡呋酯和恩替卡韦的日均费用降幅最大,2020年,两种药物的日均费用分别为3.09元和3.60元,在所有药物中最小。结论 抗乙型肝炎病毒药物的使用总体上依照指南的推荐建议,首选恩替卡韦和替诺福韦二吡呋酯,但需重视个别患者仍然使用非一线核苷(酸)类药物。Objective To analyze the application of anti-hepatitis B virus agents in 105 hospitals in 7 cities of China from 2015 to 2020. Methods Prescription data of Hepatitis B patients participating in the "Hospital Prescription Analysis" of the Chinese Pharmaceutical Association research group were randomly selected. The defined daily doses(DDDs),defined daily dose cost(DDDc),the ratio of sales amount ranking(B)and frequency of medication ranking(A),sales amount of anti-Hepatitis B agents were calculated to analyze clinical applications. Results A total of 2 999 191 prescriptions for Hepatitis B patients were collected,including 105 hopitals of 7 cities. The number of hepatitis B patients and the total sales amount of anti-hepatitis B virus agents showed a trend of first increasing and then decreasing. Male patients were significantly more than female patients.From 2015 to 2017,the most frequently used agents were entecavir and adefovir dipivoxil,but from 2018 to 2020,they were entecavir and tenofovir disoproxil fumarate. From 2015 to 2020,the defined daily dose cost of tenofovir disoproxil fumarate and entecavir decreased the most. In 2020,the defined daily dose cost of the two agents was 3. 09 yuan/day and 3. 60 yuan/day,respectively,the smallest among all drugs. Conclusions The application of anti-HBV agents was generally in accordance with the recommendations of the guidelines to select entecavir and tenofovir disoproxil fumarate. However,attention should be paid to the problem that some patients were still prescribed non-first-line nucleos(t)ide analogues agents to treat chronic hepatitis B.

关 键 词：抗乙型肝炎病毒药物 药物利用评价 临床应用 

分 类 号：R978.7[医药卫生—药品] R969.3[医药卫生—药学]